Related Experiment Video

Updated: Jun 8, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.0K

Protein-RNA interaction dynamics reveal key regulators of oncogenic KRAS-driven cancers

Ka-Yun Ban1, Yong-Woo Na2, Juhan Song1

  • 1Department of Health Science and Technology, Lee Gil Ya Cancer and Diabetes Institute, GAIHST, Incheon, 21999, Republic of Korea.

Scientific Reports
|November 7, 2024
PubMed

Insights

Oncogenic KRAS mutations alter RNA-binding protein (RBP) networks. This study identified 35 cancer-associated RBPs, revealing new therapeutic targets for KRAS-mutant cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genomics

Background:

  • KRAS is a frequently mutated oncogene in cancer, driving significant alterations in cellular signaling and gene expression.
  • RNA-binding proteins (RBPs) are crucial regulators of post-transcriptional gene expression, and their dysregulation is common in cancer.
  • The impact of oncogenic KRAS mutations on RBP-mediated post-transcriptional networks is not well understood.

Purpose of the Study:

  • To systematically investigate how oncogenic KRAS mutations affect RNA-binding protein networks.
  • To identify specific RBPs and their altered RNA-binding activities in KRAS-mutant cancers.
  • To provide a resource for understanding RBP regulation in KRAS-driven malignancies and inform therapeutic strategies.

Main Methods:

  • Systematic analysis of RNA-binding protein networks in the context of oncogenic KRAS activation.
  • Identification and characterization of RBPs exhibiting altered RNA binding in KRAS-mutant cancer cells.
  • Functional validation of key RBPs, such as PDCD11 and ELAVL2, in KRAS-mutant cancer models.

Main Results:

  • Identified 35 cancer-associated RBPs with altered RNA binding in response to oncogenic KRAS.
  • Discovered PDCD11 as essential for the viability of KRAS-mutant cancers.
  • Found ELAVL2 regulates cell migration in KRAS-mutant lung cancers.

Conclusions:

  • Oncogenic KRAS mutations significantly reshape the RNA-binding protein regulatory landscape.
  • Specific RBPs like PDCD11 and ELAVL2 are critical players in KRAS-mutant cancer progression.
  • This research offers a valuable resource and potential therapeutic targets for KRAS-mutant cancers.

More Related Videos

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein07:08

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein

Published on: January 16, 2020

5.6K
Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle10:05

Studying RNA Interactors of Protein Kinase RNA-Activated during the Mammalian Cell Cycle

Published on: March 5, 2019

6.4K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.2K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.7K